Illness caused by COVID-19

Published on Jan 1, 2021
· DOI :10.35366/97781
Jesús Carlos Briones-Garduño3
Estimated H-index: 3
(HGM: Hospital General de México),
R. Carrillo-Esper + 5 AuthorsM. D. D. León-Ponce (Academia Nacional de Medicina)
BACKGROUND: The current outbreak of pandemic coronavirus disease 2019 (COVID-19) aggravates serious need for effective therapeutics. Over recent years, drug repurposing has been accomplished as an important opportunity in drug development as it shortens the time consumed for development, besides sparing the cost and the efforts exerted in the research and development process. The FDA-approved antiparasitic drug, nitazoxanide (NTZ), has been found to have antiviral activity against different vira...
25 CitationsSource
#1Claude Guérin (French Institute of Health and Medical Research)H-Index: 59
#2Richard K. Albert (CU: University of Colorado Boulder)H-Index: 59
Last. Jordi ManceboH-Index: 34
view all 11 authors...
In ARDS patients, the change from supine to prone position generates a more even distribution of the gas-tissue ratios along the dependent-nondependent axis and a more homogeneous distribution of lung stress and strain. The change to prone position is generally accompanied by a marked improvement in arterial blood gases, which is mainly due to a better overall ventilation/perfusion matching. Improvement in oxygenation and reduction in mortality are the main reasons to implement prone position in...
29 CitationsSource
INTRODUCTION: Nitazoxanide has shown efficacy in vitro against coronavirus infections (MERS, SARS, SARS-CoV-2). The aim of this report is to describe the results of treating COVID-19 positive patients with nitazoxanide in three clinical settings: pregnancy/puerperium, hospitalized patients in an Internal Medicine Service and in an ambulatory setting. METHODOLOGY: This was a prospective follow-up and report of COVID-19 cases in three different situations, pregnant women, hospitalized patients rec...
8 CitationsSource
#1María Pilar Guallar (UAM: Autonomous University of Madrid)H-Index: 2
#2Rosa MeiriñoH-Index: 2
Last. Vicente SorianoH-Index: 30
view all 6 authors...
A relationship between the infecting dose and the risk of disease severity has not been demonstrated for SARS-CoV-2 infection Here, we report three clusters of individuals that were exposed to diverse inoculi in Madrid and overall developed divrgent clinical forms of COVID-19 Our data support that a greater SARS-CoV-2 inoculi at the time of exposure might determine a higher risk of severe COVID-19
50 CitationsSource
A COVID-19 e uma doenca nova, descoberta em dezembro de 2019, provocada pelo virus SARS-CoV-2, levando a mais de 400 mil mortes em 6 meses, no mundo inteiro. Ate momento nao ha farmacos ou vacinas capazes de atenuar os sintomas da doenca. Dessa forma, o reaproveitamento de substâncias e amplamente estudado como estrategia para determinar a eficiencia de uma substância rapidamente. O remdesivir e, ate 22 de junho de2020, o unico farmaco aprovado para o tratamento da COVID-19, em fase severa. Outr...
1 Citations
AIM: SARS-CoV-2 infection has been divided by scientific opinion into three phases: the first as asymptomatic or slightly symptomatic and the second and the third with greater severity, characterized by a hyperinflammatory and fibrotic state, responsible for lung lesions, in some cases fatal. The development of antiviral drugs directed against SARS-CoV-2 and effective vaccines is progressing; meanwhile, the best pharmacological objective is related to the management of all the complications caus...
27 CitationsSource
#1Soroush Seifirad (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 12
Cytokine storm, multiorgan failure, and particularly acute respiratory distress syndrome (ARDS) is the leading cause of mortality and morbidity in patients with COVID-19 A fulminant ARDS kills the majority of COVID-19 victims Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), is a novel anti-fibrotic agent with trivial adverse effects Pirfenidone is approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF) for patients with mild to moderate disease Pirfenidone could inhibit apoptosis, down...
19 CitationsSource
#1John H. Beigel (UC: University of California)H-Index: 1
#1John H. BeigelH-Index: 28
Last. H. Clifford Lane (UC: University of California)H-Index: 1
view all 40 authors...
Abstract Background Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious. Methods We conducte...
2,644 CitationsSource
Cited By0